The Increasing Prevalence Of Myelofibrosis Is Fueling The Market Due To Its High Occurrence Among The Aging Population Is Supporting Development Across The Primary Myelofibrosis Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Primary Myelofibrosis Market Over The Forecast Period?

The primary myelofibrosis market has experienced significant growth in recent years. It is projected to increase from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. Historically, this expansion has been influenced by factors such as limited therapeutic options, delayed diagnosis and misdiagnosis, low disease awareness, reliance on conventional treatments, and a small patient population.

The primary myelofibrosis market size is poised for robust expansion in the upcoming years. It is forecast to grow to $1.14 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This anticipated growth throughout the forecast period stems from the advancement of novel targeted therapies, a rise in clinical trial engagements, improvements in genetic and molecular diagnostics, increasing investment in hematology research, and the growing acceptance of personalized medicine. Prominent trends for the forecast period encompass heightened awareness and prompt diagnosis of primary myelofibrosis, an escalation in targeted therapies and individualized treatment approaches, greater integration of advanced diagnostic tools, an expansion of clinical trials and research endeavors, and a dedicated focus on patient support programs and disease management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Market Drivers Are Helping Shape The Primary Myelofibrosis Market Expansion?

The primary myelofibrosis market is set to experience growth driven by the escalating prevalence of myelofibrosis. Myelofibrosis is a rare bone marrow cancer that interferes with normal blood cell production, causing significant scarring in the bone marrow and leading to severe anemia, weakness, fatigue, and an enlarged spleen. This rise in prevalence is largely attributable to the aging population, given that the condition predominantly impacts individuals over the age of 60, with longer life expectancies contributing to more diagnoses. The increased prevalence also positively influences the management of primary myelofibrosis by stimulating research, improving early detection, expanding treatment choices, and fostering superior clinical guidelines and specialized care. For example, a November 2024 report by the National Institute for Health and Care Excellence highlighted a myelofibrosis prevalence of 3.2 per 100,000 people and an incidence rate of 0.6 per 100,000 in the UK. Consequently, the growing prevalence of myelofibrosis is a key driver for the primary myelofibrosis market.

How Is Segment Classification Applied In The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

What Trends Are Affecting The Growth Of The Primary Myelofibrosis Market?

Leading companies active in the primary myelofibrosis market are concentrating on developing advanced products, such as Janus kinase 2 inhibiting tablets, to enhance symptom management and slow down disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral drugs that impede the function of the JAK2 enzyme, which is implicated in the irregular signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and decelerating the disease’s advancement. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology company based in Korea, introduced Omjjara (momelotinib), a new treatment for myelofibrosis. This treatment is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, an enlarged spleen, and fatigue. Its approval is supported by clinical trial data demonstrating significant improvements in anemia, spleen size, and overall symptoms when compared to existing treatments.

Which Companies Form The Competitive Landscape Of The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Access The Complete Primary Myelofibrosis Market Report:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Has The Strongest Presence In The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Primary Myelofibrosis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795